Fig. 2: Amino-acid sequences of the N, R, and C fragments. | Nature Communications

Fig. 2: Amino-acid sequences of the N, R, and C fragments.

From: Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine

Fig. 2

Sequence and localization of the three P. vivax CS LSP (N, R, and C) fragments used as immunogens. The N polypeptide corresponded to N-terminal amino acids (aa) 20–96 (N-term), and the C peptide to C-terminal aa 301–372 (C-term). The R peptide VK210 (type I) corresponded to a construct based on the first central repeat (aa 96–104) in tandem three times and collinearly linked to a universal T-cell epitope (ptt-30) derived from tetanus toxin. For the first dose a peptide mixture of N-terminal (term) and fragments (1N:1C) (50 μg/each peptide) was used, whereas for the second and third doses the peptide mixture included N-term, C-term, and R fragments (1N:1C:1R) (50 μg/each peptide).

Back to article page